BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35358003)

  • 1. Cell senescence, rapamycin and hyperfunction theory of aging.
    Blagosklonny MV
    Cell Cycle; 2022 Jul; 21(14):1456-1467. PubMed ID: 35358003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin, proliferation and geroconversion to senescence.
    Blagosklonny MV
    Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Oncotarget; 2015 Sep; 6(27):23238-48. PubMed ID: 26177051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gerosuppression by pan-mTOR inhibitors.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2016 Dec; 8(12):3535-3551. PubMed ID: 28077803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geroconversion: irreversible step to cellular senescence.
    Blagosklonny MV
    Cell Cycle; 2014; 13(23):3628-35. PubMed ID: 25483060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging.
    Blagosklonny MV
    Aging (Albany NY); 2012 Mar; 4(3):159-65. PubMed ID: 22394614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.
    Wang R; Yu Z; Sunchu B; Shoaf J; Dang I; Zhao S; Caples K; Bradley L; Beaver LM; Ho E; Löhr CV; Perez VI
    Aging Cell; 2017 Jun; 16(3):564-574. PubMed ID: 28371119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-aging: senolytics or gerostatics (unconventional view).
    Blagosklonny MV
    Oncotarget; 2021 Aug; 12(18):1821-1835. PubMed ID: 34504654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEK drives cyclin D1 hyperelevation during geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Death Differ; 2013 Sep; 20(9):1241-9. PubMed ID: 23852369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.
    Leontieva OV; Blagosklonny MV
    Oncotarget; 2014 Dec; 5(24):12715-27. PubMed ID: 25587030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular senescence: when growth stimulation meets cell cycle arrest.
    Blagosklonny MV
    Aging (Albany NY); 2023 Feb; 15(4):905-913. PubMed ID: 36805938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
    Leontieva OV; Blagosklonny MV
    Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of replicative senescence by rapamycin in rodent embryonic cells.
    Pospelova TV; Leontieva OV; Bykova TV; Zubova SG; Pospelov VA; Blagosklonny MV
    Cell Cycle; 2012 Jun; 11(12):2402-7. PubMed ID: 22672902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial replicative senescence delayed by the inhibition of MTORC1 signaling involves MicroRNA-107.
    Khor ES; Wong PF
    Int J Biochem Cell Biol; 2018 Aug; 101():64-73. PubMed ID: 29857052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin and the inhibition of the secretory phenotype.
    Wang R; Sunchu B; Perez VI
    Exp Gerontol; 2017 Aug; 94():89-92. PubMed ID: 28167236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia suppresses conversion from proliferative arrest to cellular senescence.
    Leontieva OV; Natarajan V; Demidenko ZN; Burdelya LG; Gudkov AV; Blagosklonny MV
    Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13314-8. PubMed ID: 22847439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From rapalogs to anti-aging formula.
    Blagosklonny MV
    Oncotarget; 2017 May; 8(22):35492-35507. PubMed ID: 28548953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.
    Laberge RM; Sun Y; Orjalo AV; Patil CK; Freund A; Zhou L; Curran SC; Davalos AR; Wilson-Edell KA; Liu S; Limbad C; Demaria M; Li P; Hubbard GB; Ikeno Y; Javors M; Desprez PY; Benz CC; Kapahi P; Nelson PS; Campisi J
    Nat Cell Biol; 2015 Aug; 17(8):1049-61. PubMed ID: 26147250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue.
    Leontieva OV; Blagosklonny MV
    Cell Cycle; 2014; 13(4):509-15. PubMed ID: 24496328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2010 Dec; 2(12):924-35. PubMed ID: 21212465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.